Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer

2 Information about fulvestrant

**Information about fulvestrant**
Marketing authorisation	Fulvestrant (Faslodex, AstraZeneca) is indicated for 'the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy (licence extension under appraisal) or with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy' (appraised in NICE technology appraisal guidance on fulvestrant for the treatment of locally advanced or metastatic breast cancer).
Recommended dose and schedule	The recommended dosage is 500 mg intramuscularly into the buttocks as 2×5‑ml injections (1 in each buttock) on days 1, 15 and 29, and then once monthly (until disease progression).
Price	A pack of 2×5‑ml (50 mg/ml) prefilled syringes costs £522.41 (NHS indicative price, British national formulary online, August 2017). Costs may vary in different settings because of negotiated procurement discounts.